Literature DB >> 7037265

Captopril kinetics.

K L Duchin, S M Singhvi, D A Willard, B H Migdalof, D N McKinstry.   

Abstract

Captopril, an angiotensin-converting enzyme inhibitor with antihypertensive properties, was given by mouth and intravenously in 10-mg doses to five healthy subjects. After intravenous dosing, semilogarithmic plots of captopril blood levels : time showed a triexponential decay. Data were analyzed using an open three-compartment model. The average volume of distribution (Vd) was 0.2 l/kg for the central compartment and 2 l/kg for the elimination (beta) phase. The Vd at steady-state was 0.7 l/kg. The total body clearance of captopril averaged 0.8 l/kg/hr and the mean blood half-life during the beta phase was 1.9 hr. In the 0- to 96-hr urine, after intravenous and oral drug, excretion of radioactivity accounted for 87% and 61% of dose. In the 0- to 24-hr urine, averages of 38% (intravenous) and 24% (oral) of the doses were excreted as unchanged captopril. Absolute absorption of the radioactive oral dose was 71% and the absolute oral bioavailability of captopril was 62%.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7037265     DOI: 10.1038/clpt.1982.59

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  34 in total

Review 1.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

3.  Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man.

Authors:  S M Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Preparation of a matrix type multiple-unit gastro retentive floating drug delivery system for captopril based on gas formation technique: in vitro evaluation.

Authors:  Lingam Meka; Bhaskar Kesavan; Krishna Mohan Chinnala; Venkateswarlu Vobalaboina; Madhusudan Rao Yamsani
Journal:  AAPS PharmSciTech       Date:  2008-05-06       Impact factor: 3.246

5.  Pharmacokinetics of intravenous captopril in healthy men.

Authors:  W A Creasey; R A Morrison; S M Singhvi; D A Willard
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Pharmacokinetics of intravenous cilazaprilat in normal volunteers.

Authors:  E M Whitehead; G E Walters; P E Williams; G D Johnston
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

7.  Captopril pharmacokinetics.

Authors:  G Deray
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

8.  Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.

Authors:  C Richer; B Giroux; P F Plouin; B Maarek; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Authors:  J Hoyer; K L Schulte; T Lenz
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

Review 10.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.